David Cohn, MD, on Clinician Awareness About the COVID-19 Vaccine in Patients With Cancer

Article

A cancer care expert from The Ohio State University Comprehensive Cancer Hospital talks about what patients and their providers need to know about the COVID-19 vaccine.

CancerNetwork® was joined by David Cohn, MD, director of the Gynecologic Cancer Research at The Ohio State University Comprehensive Cancer Hospital, to discuss what clinicians treating patients with cancer should know about in regard to the coronavirus disease 2019 (COVID-19) vaccine and the effects in their patients.

Multiple stakeholders in the cancer community as well as The Centers for Disease Control (CDC) and Prevention have indicated that patients on active cancer therapy are amongst those with a critical need for immunization against the COVID-19 virus. In January 2021, the National Comprehensive Cancer Network released guidance regarding vaccinations in patients with cancer.

“Patients who are on active treatment for their cancer—meaning chemotherapy, radiation therapy, cellular therapy, or immunotherapy–are all at increased risk of contracting COVID-19 and are at increased risk of having severe complications or death due to COVID-19 were they to become infected,” Cohn said in the interview. “It’s critically important that all of our patients with cancer who are on active therapy are counseled about the benefits of COVID-19 vaccination and to be aware of [its] side effects. In our practice, we encourage patients to get vaccinated.”

In the interview, Cohn discussed adverse effects of the vaccine as well as individual state mandates on vaccine prioritization.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences™ Medical World News®, airing daily on all MJH Life Sciences™ channels.

Related Videos
Cancer vaccines are a “cross-cutting approach” that may be applicable across several cancer types, according to Catherine J. Wu, MD.
mRNA may be a potential modality for developing cancer-based vaccines, according to Catherine J. Wu, MD.
Analyzing the KRAS mutation across various cancer types may be a worthwhile target when using a cancer vaccine or immunotherapy, says Catherine J. Wu, MD.
The AACR Health Disparities Report highlights the changes needed to achieve health equity for patients with cancer.
Robert A. Winn, MD, gives insight into how institutions and community practices can improve access to cancer care.
In the October edition of Snap Recap, we review the latest FDA news and the vote from the last ODAC meeting.
In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.
Implementing tax benefits for manufacturers who produce chemotherapy drugs may be one solution to increase drug production in the United States, according to Lucio N. Gordan, MD.
Lucio N. Gordan, MD, describes how his practice deals with increasing costs of limited chemotherapy agents to ensure that patients with cancer continue to receive treatment.
Related Content
Patients with cancer who underwent surgery during the COVID-19 pandemic were also more likely to have respiratory complications.

Higher Mortality Risk Reported in Cancer Surgery During COVID-19 Pandemic

May 14th 2024
Article

Patients with cancer who underwent surgery during the COVID-19 pandemic were also more likely to have respiratory complications.

Edward S. Kim, MD, MBA, and Richard T. Lee, MD discuss how integrative oncology techniques such as acupuncture have impacted patient quality of life at their practice.

Creating a First-of-Its-Kind Integrative Oncology Program at City of Hope

March 18th 2024
Podcast

Edward S. Kim, MD, MBA, and Richard T. Lee, MD discuss how integrative oncology techniques such as acupuncture have impacted patient quality of life at their practice.

The regulatory agency has set a Prescription Drug User Fee Act date of February 28, 2025, for subcutaneous nivolumab in multiple solid tumors.

FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications

May 6th 2024
Article

The regulatory agency has set a Prescription Drug User Fee Act date of February 28, 2025, for subcutaneous nivolumab in multiple solid tumors.

Primary care physicians cannot afford to dismiss younger people who present with symptoms of cancer in the face of increasing cancer incidence, according to Monique Gary, DO, MSc, FACS.

Addressing Rising Cancer Incidence and Burden in Younger Populations

March 11th 2024
Podcast

Primary care physicians cannot afford to dismiss younger people who present with symptoms of cancer in the face of increasing cancer incidence, according to Monique Gary, DO, MSc, FACS.

Additional research may be necessary to validate the efficacy of telehealth interventions in clinical activities for patients with cancer.

Cancer Symptom Improvements Occur With Telehealth Exercise Program

April 27th 2024
Article

Additional research may be necessary to validate the efficacy of telehealth interventions in clinical activities for patients with cancer.

Lack of energy, difficulty with sleeping, and pain were some of the most common symptoms reported in older patients with cancer.

Elderly Cancer Populations Have Inconsistent Symptom Burden/Clusters

April 26th 2024
Article

Lack of energy, difficulty with sleeping, and pain were some of the most common symptoms reported in older patients with cancer.